scispace - formally typeset
Y

Yu Chuan Chien

Researcher at China Medical University (Taiwan)

Publications -  9
Citations -  151

Yu Chuan Chien is an academic researcher from China Medical University (Taiwan). The author has contributed to research in topics: Docosahexaenoic acid & Randomized controlled trial. The author has an hindex of 5, co-authored 8 publications receiving 79 citations.

Papers
More filters
Journal ArticleDOI

Melatonergic agonist regulates circadian clock genes and peripheral inflammatory and neuroplasticity markers in patients with depression and anxiety.

TL;DR: RMT treatment is able to restore phase-shifted melatonin markers, normalized the altered expression of the circadian genes, the levels of inflammatory cytokines and neurotrophins in patients with insomnia comorbid anxiety and depression.
Journal ArticleDOI

Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder - Results from a randomized controlled trial.

TL;DR: N-3 PUFAs supplementation may provide a treatment option for a subpopulation of patients with CVDs comorbid MDD, and when stratified with depression severity, n-3PUfAs supplementation improved core depression symptoms in the very severe MDD group.
Journal ArticleDOI

Clinical Efficacy and Biological Regulations of ω–3 PUFA-Derived Endocannabinoids in Major Depressive Disorder

TL;DR: Treatments enriched with EPA increased plasma EPEA levels, which was positively associated with clinical remission, which may suggest that levels of plasma E PEA play a potential novel endogenous therapeutic target in MDD.
Journal ArticleDOI

Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms.

TL;DR: The results demonstrated that RMT and EPA synergistically provide effective neuroprotective, anti-oxidative/inflammatory effect against oxidative stress, and provides pre-clinical evidence to conduct future clinical trials of using n-3 PUFAs/RMT combination in depressive disorders.